Posted Date: 4/10/2017

SteadyMed Completes Clinical Validation Study of Trevyent Study; Confirms Performance of PatchPump Technology

SteadyMed Ltd. recently announced the successful completion of a clinical study for its lead drug product candidate, Trevyent. Trevyent is a combination of the company’s treprostinil and PatchPump prefilled, disposable infusion system that is in development for the treatment of Pulmonary Arterial Hypertension (PAH). The company remains on track for a New Drug Application (NDA) submission for Trevyent to treat PAH, in the second quarter of 2017.

This study enrolled 60 healthy adult volunteers in an in-clinic setting, and was intended to provide clinical validation of the performance of the Trevyent product. Each subject was administered one PatchPump device containing a placebo formulation, to be used for 48 hours while subjects otherwise carried on with normal daily and nighttime activities. The objective of the study was to evaluate the essential safety and performance functions of Trevyent’s proprietary delivery system, including dose accuracy and precision, as well as tolerability for on-body application of the product. The results indicate that the PatchPump devices performed as intended in all categories of evaluation.

"We are delighted to announce the completion of this important study for Trevyent. This milestone brings us one step closer to the planned submission of the Trevyent NDA, which remains on track for the second quarter. We believe that the completion of this study, with units performing exactly as intended, confirms the utility of Trevyent over its intended 48-hour duration of single-unit use," said Jonathan M.N. Rigby, President and CEO of SteadyMed. “Trevyent is a highly differentiated product that has been specifically designed to address clear unmet needs in the PAH community, and we look forward to bringing Trevyent to patients suffering from PAH, if approved by the FDA, in 2018."

SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent, a development stage drug product that combines SteadyMed's PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). SteadyMed intends to commercialize Trevyent in the US and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada, and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For more information, visit www.steadymed.com.

Related Taxonomy
Popularity:
This record has been viewed 1319 times.





















- SHL


Click here to see the showcases


BIO Investor Forum
October 17-18, 2017
The Westin St. Francis, San Francisco, CA US
 
Partnership Opportunities in Drug Delivery (PODD)
October 19-20
Boston, MA

CPhI Worldwide
October 24-26
Frankfurt, Germany

Universe of Prefilled Syringes & Injection Devices Europe
November 7-8
Vienna, Austria

AAPS
November 12-17
San Diego, CA

Pre-Filled Syringes Europe
January 17-18, 2018
Copthorne Tara Hotel, London UK

Drug Delivery Partnerships
January 22-24 Palm Beach, FL

3rd Annual Drug Development Networking Summit
March 8, 2018  Hilton Hotel Parsippany NJ
 
PDA Annual Meeting
March 19-21 Orlando, FL
 
CPhI North America
April 24-26 Philadelphia, PA 
 
INTERPHEX
April 17-19 New York City
 
RDD (Respiratory Drug Delivery)
April 22-26 Tucson, AZ
 
BIO 2018
June 4-7 Boston, MA
 
Controlled Release Society Meeting
July 23-25 New York City
 
Universe of Prefilled Syringes & Injection Devices
October 8-9 Orlando, FL
 



Copyright © 2017  Drug Development & Delivery All Rights Reserved. Privacy Policy / Terms and Conditions